arrow
P

Peter Farrehi

university of texas system
H指数:13
被引数:997

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients

阿司匹林用于男性和女性患者动脉粥样硬化性心血管疾病二级预防的剂量

2024-09-011
PRE
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease

年龄和阿司匹林剂量在动脉粥样硬化性心血管疾病二级预防中的作用

2024-02-201
OAAI
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial
2023-11-014
OAAI
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors

阿司匹林剂量用于P2Y12抑制剂治疗患者动脉粥样硬化性心血管疾病的二级预防

2023-10-171
OAAI
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE
2023-10-010
OAAI
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial

阿司匹林剂量在心血管疾病和糖尿病中的比较有效性: 适应性试验的亚组分析

2023-09-151
OAAI
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

阿司匹林给药在心血管疾病中的比较效果

2021-05-27167
OA
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

阿司匹林给药在心血管疾病中的比较效果

2021-05-27167
PRE
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

阿司匹林剂量的基本原理和设计-以患者为中心的试验评估益处和长期有效性 (适应性) 试验

2020-05-0168
OAAI